Adalvo Overview
- Year Founded
-
2018
- Status
-
Private
- Employees
-
283
- Latest Deal Type
-
Buyout/LBO
- Financing Rounds
-
4
- Investments
-
1
Adalvo General Information
Description
Operator of a pharmaceutical company that focuses primarily on the sale of services to companies. The company operates according to a business model and offers smart services to form a network of partners to achieve its goals, thus delivering high-quality products and services to partners.
Contact Information
Website
www.adalvo.comCorporate Office
- Malta Life Sciences Park, Building 1
- Level 4, Sir Temi Zammit Buildings, San Gwann Industrial Estate
- San Gwann, SGN 3000
- Malta
Corporate Office
- Malta Life Sciences Park, Building 1
- Level 4, Sir Temi Zammit Buildings, San Gwann Industrial Estate
- San Gwann, SGN 3000
- Malta
Adalvo Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Adalvo Patents
Adalvo Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026022235-A1 | A fixed-dose pharmaceutical composition comprising (2s)-2-[(4,6-dimethylpyrimidin-2-yl)oxy]-3-methoxy-3,3-diphenylpropanoic acid and (6r,12ar)-6-(1,3-benzodioxol-5-yl)-2-methyl-2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione | Pending | 24-Jul-2024 | ||
| EP-4684777-A1 | A fixed-dose pharmaceutical composition comprising (2s)-2-[(4,6-dimethylpyrimidin-2-yl)oxy]-3-methoxy-3,3-diphenylpropanoic acid and (6r,12ar)-6-(1,3-benzodioxol-5-yl)-2-methyl-2,3,6,7,12,12a-hexahydropyrazino{1',2:1,6]pyrido[3,4-b]indole-1,4-dione | Pending | 24-Jul-2024 | ||
| EP-4780459-A1 | Pharmaceutical compositions comprising riociguat as active ingredient and other relevant excipients | Pending | 20-Sep-2023 | ||
| WO-2025063911-A1 | Pharmaceutical compositions comprising riociguat as active ingredient and other relevant excipients | Inactive | 20-Sep-2023 | ||
| EP-4431083-A1 | Formulation of dalbavancin | Inactive | 16-Mar-2023 | A61K9/0019 |
Adalvo Signals
Adalvo Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Adalvo Investments (1)
Adalvo’s most recent deal was a Buyout/LBO with Onsolis. The deal was made on 02-Aug-2023.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Onsolis | 02-Aug-2023 | Buyout/LBO | Buildings and Property |
Adalvo FAQs
-
When was Adalvo founded?
Adalvo was founded in 2018.
-
Where is Adalvo headquartered?
Adalvo is headquartered in San Gwann, Malta.
-
What is the size of Adalvo?
Adalvo has 283 total employees.
-
What industry is Adalvo in?
Adalvo’s primary industry is Pharmaceuticals.
-
Is Adalvo a private or public company?
Adalvo is a Private company.
-
What is Adalvo’s current revenue?
The current revenue for Adalvo is .
-
Who are Adalvo’s investors?
EQT and Aztiq Pharma Partners have invested in Adalvo.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process